CorVista Health Inc. has appointed Guido Neels and Dino Trevisani to its Board of Directors. The pair have more than three decades of global technology and healthcare leadership experience.

Neels brings more than four decades of experience in global healthcare leadership and investment. He currently serves as operating partner at EW Healthcare Partners and was formerly chief operating officer (COO) of Guidant Corporation. At EW, he has played a central role in building and leading the firm’s medical device investment practice. Since joining EW in 2006, Neels has guided multiple growth-stage companies, and he currently serves on the boards of Enercon Technologies, Bioventus (both EW Healthcare Partners portfolio companies), and Impulse Dynamics.

“I have spent my career helping advance medical innovation, and CorVista represents one of the most exciting opportunities I have seen. The company is addressing one of the most pressing challenges in cardiovascular disease and has a differentiated strategy and approach to tackle this problem,” Neels said. “As one of the first companies to bring AI to healthcare, CorVista’s diagnostic platform has the potential to change how and where patients are diagnosed, eliminating delays that often are detrimental for patients. I look forward to contributing my experience to support the company’s next phase of growth and impact on global health.”

Previously, as Guidant Corporation COO, he played a pivotal role in building a global interventional cardiology company, culminating in Guidant’s $27 billion acquisition by Boston Scientific Corp.—one of the largest transactions in medtech history. During that time, he supervised operations across four global divisions: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery, and Endovascular Solutions while also leading multiple corporate functions, including sales operations, corporate communications, marketing, investor relations, and government relations. Earlier in his career, Neels held general management, sales, and marketing leadership roles at Eli Lilly & Company in the United States and Europe.

“Guido’s decision to join our board is a strong validation of CorVista’s mission and momentum, and his deep expertise in scaling medtech companies and in venture capital will be invaluable to both our leadership team and the company,” CorVista Health CEO Adrian Lam said. “His leadership experience at Guidant and his strategic perspective from decades of investing will strengthen our team as we enter our next phase of growth and scale commercially.”

Neels earned a business engineering degree from the University of Leuven in Belgium and an MBA from Stanford University.

Trevisani is the original founder of CorVista, and has extensive global technology expertise. He spent 36 years at IBM where he held multiple senior leadership roles, including serving as president and general manager of IBM Canada, global managing director of Technology, and general manager of Financial Services for IBM North America. He currently serves as chief growth officer at Unqork, a leader in regenerative applications and the future of artificial intelligence (AI) enterprise application development. Unqork is built on data driven architecture and entirely separates the logic from code. Trevisani also serves as an advisor to Tata Communications, a global digital ecosystem enablers and telecommunications companies, and part of the Tata Group.

“Having been part of CorVista Health’s founding, I’m thrilled to return to the board at this defining moment for the company,” Trevisani commented. “CorVista’s technology has the power to transform how cardiovascular disease is diagnosed and managed, bringing faster, more accessible insights to physicians and patients when they matter most. The company has made tremendous strides in advancing its platform and readiness for commercialization, and I’m eager to help guide this next phase of growth, innovation, and impact on global heart health.”

Trevisani earned a bachelor’s degree in commerce and business from McMaster University, an MBA in accounting and finance from Cornell University, and an MBA from Queen’s University.

“Dino’s track record of driving growth and innovation across the technology and financial services sectors, coupled with his early role in CorVista’s founding, brings invaluable perspective to our board,” CorVista Board Chairman Tim Attebery stated. “Having one of our original founders return at this pivotal stage is a powerful validation of the company’s trajectory and the clear opportunities ahead. His experience scaling global organizations and advancing transformative technologies will be invaluable as CorVista enters its next phase of commercial growth and seeks to accelerate its impact on global cardiovascular care.”

CorVista Health is striving to transform cardiovascular care with diagnostics that shorten the path from symptoms to diagnosis, empowering earlier treatment and better patient outcomes. The company enables more equitable care by providing access to immediately actionable, high-quality cardiovascular test results for previously underserved patient populations.